Results 61 to 70 of about 301,526 (300)

Biomimetic Nanovaccine Integrating Dendritic Cell Exosomes with Tumor Cell Membranes for Sustained Prophylaxis Against Glioblastoma

Advanced Functional Materials, EarlyView.
We have developed DEX/GM, an all‐natural, personalizable hybrid vaccine designed by coating dendritic cell‐derived exosomes (DEX) onto tumor cell membranes (GM) for sustained prophylaxis against glioblastoma (GBM). ABSTRACT Glioblastoma (GBM), one of the most aggressive and lethal brain tumors, remains incurable with a poor clinical prognosis.
Shanshan Li, Dongya Zhang, Shiyu Wang, Changhe Pang, Meng Zheng, Bingyang Shi, Yan Zou   +6 more
wiley   +1 more source

Poly(lactic‐co‐glycolic acid) Nanoparticles for IL‐12 Self‐Amplifying RNA Delivery in Glioblastoma Models

Advanced Functional Materials, EarlyView.
xxxx. ABSTRACT Glioblastoma (GBM) remains one of the most lethal brain cancers, with median survival rarely exceeding 15 months after diagnosis. Interleukin‐12 (IL‐12) is a potent immunostimulatory cytokine capable of reshaping the tumor microenvironment (TME), yet its clinical translation is hindered by systemic toxicity and short half‐life. RNA‐based
Fatima Hameedat, Johan Sebastian Lopez‐Parra, Willem M. H. Hoogaars, Emma Dijkstra, Cynthia Huang, Irafasha C. Casmil, Anna K. Blakney, Peter Olinga, Barbara Rothen‐Rutishauser, Hélder A. Santos, Alke Petri‐Fink, Flávia Sousa   +11 more
wiley   +1 more source

Human monoclonal antibody F61 nasal spray effectively protected high-risk populations from SARS-CoV-2 variants during the COVID-19 pandemic from late 2022 to early 2023 in China

Emerging Microbes and Infections
Following the national dynamic zero-COVID strategy adjustment, the utilization of broad-spectrum nasal neutralizing antibodies may offer an alternative approach to controlling the outbreak of Omicron variants between late 2022 and early 2023 in China ...
Ying Liu, Jiayou Zhang, Wen Liu, Yongbing Pan, Shunan Ruan, Xuanxuan Nian, Wei Chen, Lina Sun, Qiangling Yin, Xin Yue, Qingliang Li, Fang Gui, Cong Wu, Shuzhen Wang, Yunkai Yang, Zhaofei Jing, Feiguang Long, Zejun Wang, Zeyu Zhang, Chaolin Huang, Kai Duan, Mifang Liang, Xiaoming Yang   +22 more
doaj   +1 more source

Strategies for Loading and Releasing Peptide Therapeutics in Biodegradable Carriers

Advanced Functional Materials, EarlyView.
A biodegradable carrier‐based peptide delivery system is a powerful treatment platform for diverse diseases, owing to its superior therapeutic efficacy and low toxicity. This review examines the conventional peptide‐loaded carrier fabrication process and its current limitations.
Wookyoung Jang, Ki Wan Bong
wiley   +1 more source

Immune Imprinting Identified in Phage-Display Antibody Libraries Derived from Early Wild-Type and Late Omicron COVID-19 Convalescents

Viruses
The rapid evolution of SARS-CoV-2, particularly the emergence of Omicron subvariants, has significantly reduced the efficacy of existing vaccines and monoclonal antibodies.
Boyang Li, Mengxuan Wang, Fang Huang, Wei Wu, Jiaxin Fan, Lu Yang, Yongbing Pan, Mifang Liang, Kai Duan   +8 more
doaj   +1 more source

Long-lasting cross-protection against influenza A by neuraminidase and M2e-based immunization strategies [PDF]

, 2016
There is mounting evidence that in the absence of neutralizing antibodies cross-reactive T cells provide protection against pandemic influenza viruses. Here, we compared protection and CD8+ T cell responses following challenge with H1N1 2009 pandemic and
Callewaert, Nico, Fiers, Walter, Saelens, Xavier, Schepens, Bert, Schotsaert, Michael, Smet, Anouk, Stegalkina, Svetlana, Vanderschaeghe, Dieter, Vogel, Thorsten U, Ysenbaert, Tine   +9 more
core   +2 more sources

Establishing a Model Precursor System: Over a Decade of Research on Carbon Dots from the Citric Acid‐Urea System

Advanced Functional Materials, EarlyView.
The citric acid/urea (CA‐Urea) precursor system offers a versatile, scalable route to carbon dots with tunable luminescence and multifunctionality. Mechanistic insights into precursor chemistry and reaction parameters have enabled doping, surface modification, and hybridization strategies, yielding CDs for luminescent devices, sensing, catalysis ...
Yupeng Liu, Zhiqi Cai, Xiangxin Sun, Hanyi Zhang, Yiming Hao, Jun Wu, Zekun Yan, Xue Wu, Yiqi Liang, Liming Wang, Songnan Qu   +10 more
wiley   +1 more source

Evaluation of the Robustness Verification of Downstream Production Process for Inactivated SARS-CoV-2 Vaccine and Different Chromatography Medium Purification Effects

Vaccines
Background: Large-scale vaccine production requires downstream processing that focuses on robustness, efficiency, and cost-effectiveness. Methods: To assess the robustness of the current vaccine production process, three batches of COVID-19 Omicron BA.1 ...
Jia-Hui Pang, Chang-Fu Guo, Peng-Liang Hao, Sheng-Li Meng, Jing Guo, Dou Zhang, Ya-Qi Ji, Ping-Gang Ming   +7 more
doaj   +1 more source

Exploring an Alternative to mRNA Vaccine Cold Chain Storage: MRNA‐Lipid Nanoparticle Stability When Dried in a Polymer Matrix

Advanced Functional Materials, EarlyView.
The nanostructure, size, and function of mRNA‐loaded lipid nanoparticles are evaluated before drying, within polymer microneedles, and after rehydration. The results reveal the polymer and LNP loadings required to recover nanostructure and preserve the delivery performance in dry‐state formulations.
Brendan P. Dyett, Shahad K. Alsaiari, John L. Daristotle, Timothy A. Forster, Alicia Lau, Dhruv Varshney, Rania Afaneh, Andrew R. Hanna, Charles Sloane, David Mankus, Haitao Yu, Jiali Zhai, DongSoo Yun, Lisa H. Tostanoski, Abigail Lytton‐Jean, Dan H. Barouch, Charlotte E. Conn, Robert Langer, Ana Jaklenec, Calum J. Drummond   +19 more
wiley   +1 more source

Child mortality following standard, medium or high titre measles immunization in West Africa [PDF]

, 1996
The World Health Organization (WHO) recommended the use of high titre measles vaccine in 1989. Subsequent long term follow-up of several trials yielded results suggesting higher mortality among children inoculated with medium and high titre vaccines ...
Aaby, Peter, Fine, P., Knudsen, K.M., Samb, Badara, Simondon, François, Sterne, J., Whittle, H.. Rowe, M.   +6 more
core   +1 more source